New therapies for uveal melanoma

From 2016-01-01 to 2020-12-31, ongoing project | UM Cure 2020 Website

Project details

<table>
<thead>
<tr>
<th>Total cost:</th>
<th>Topic(s):</th>
</tr>
</thead>
<tbody>
<tr>
<td>EUR 7 971 101,25</td>
<td>PHC-14-2015 - New therapies for rare diseases</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EU contribution:</th>
<th>Call for proposal:</th>
</tr>
</thead>
<tbody>
<tr>
<td>EUR 6 183 456,25</td>
<td>H2020-PHC-2015-two-stage See other projects for this call</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Coordinated in:</th>
<th>Funding scheme:</th>
</tr>
</thead>
<tbody>
<tr>
<td>France</td>
<td>RIA - Research and Innovation action</td>
</tr>
</tbody>
</table>

Objective

Uveal melanoma (UM) is a rare intraocular tumour with an incidence of 5 cases per million individuals per year. Up to 50% of UM patients develop metastases, most often in the liver, and these are invariably fatal. Despite new discoveries in the genetic and molecular background of the primary tumour, little is known about the metastatic disease; furthermore, there is no therapy to either prevent or treat UM metastases. In UM Cure 2020, we aim to identify and validate at the preclinical level novel therapeutic approaches for the treatment of UM metastases. For this purpose, the consortium brings together the major experts of UM in both patient care and basic/translational/clinical research, as well as patient representatives. An ambitious multidisciplinary approach is proposed to move from patient tissue characterisation to preclinical evaluation of single or combinations of drugs. This approach includes the characterisation of the genetic landscape of metastatic UM and its microenvironment, proteomic studies to address signal pathway deregulation and establishment of novel relevant in vitro and in vivo UM models. We also aim to validate accurate surrogate endpoint biomarkers to evaluate therapies and detect metastases as early as possible. Underpinning this will be the UM Cure 2020 virtual biobank registry, linking existing biobanks into a harmonised network, which will prospectively collect primary and metastatic UM samples. Together, our approach will lead to the identification of new therapies, allowing the initiation of UM-dedicated clinical trials sponsored by academia or pharma. Dissemination of results will include the building of a patient network across the countries as part of the consortium as well as a dedicated UM patient and caregiver’s data portal as part of the UM Cure 2020 website, in order to increase patient information and disease awareness.

Related information

Report Summaries

Periodic Reporting for period 2 - UM Cure 2020 (New therapies for uveal melanoma)
Coordinator

INSTITUT CURIE
rue d’Ulm 26
75231 PARIS
France
EU contribution: EUR 1 659 000

Activity type: Research Organisations
Contact the organisation

Participants

ACADEMISCH ZIEKENHUIS LEIDEN
ALBINUSDREEF 2
2333 ZA LEIDEN
Netherlands
EU contribution: EUR 1 021 540

Activity type: Higher or Secondary Education Establishments
Contact the organisation

UNIVERSITEIT LEIDEN
RAPENBURG 70
2311 EZ LEIDEN
Netherlands
EU contribution: EUR 434 376,25

Activity type: Higher or Secondary Education Establishments
Contact the organisation

THE UNIVERSITY OF LIVERPOOL
BROWNLOW HILL 765 FOUNDATION BUILDING
L69 7ZX LIVERPOOL
United Kingdom
EU contribution: EUR 358 604

Activity type: Higher or Secondary Education Establishments
Contact the organisation

THE UNIVERSITY OF MANCHESTER
OXFORD ROAD
M13 9PL MANCHESTER
United Kingdom
EU contribution: EUR 993 956

Activity type: Higher or Secondary Education Establishments
Contact the organisation
UNIWERSYTET JAGIELLONSKI
Ul. Golebia 24
31007 KRAKOW
Poland
See on map

Activity type: Higher or Secondary Education Establishments
Contact the organisation

KAISERSTRASSE 12
76131 KARLSRUHE
Germany
See on map

Activity type: Higher or Secondary Education Establishments
Contact the organisation

FUNDACAO D. ANNA SOMMER CHAMPALIMAUD E DR. CARLOS MONTEZ CHAMPALIMAUD
AVENIDA BRASILIA CENTRO DE INVESTIGACAO DA FUNDACAO CHAMP ALMAUD
1400 038 LISBOA
Portugal
See on map

Activity type: Research Organisations
Contact the organisation

MELANOMA PATIENT NETWORK EUROPE
FJALLBO SELKNA 152
75597 UPPSALA
Sweden
See on map

Activity type: Other
Contact the organisation

PAMGENE INTERNATIONAL BV
WOLVENHOEK 10-12
5211 HH DEN HAAG
Netherlands
See on map

Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
Contact the organisation
PEP THERAPY
4 RUE PIERRE FONTAINE CAMPUS 3
91058 EVRY
France
EU contribution: EUR 191 500

Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
Contact the organisation

SEEDING SCIENCE
19 RUE DE LA MARE
75020 PARIS
France
EU contribution: EUR 216 875

Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
Contact the organisation

UNIVERSITA DEGLI STUDI DI TRENTO
VIA CALEPINA 14
38122 TRENTO
Italy
EU contribution: EUR 304 187,50

Activity type: Higher or Secondary Education Establishments
Contact the organisation

Last updated on 2017-08-17
Retrieved on 2019-08-09

© European Union, 2019